-
Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing
Hot melt extrusion (HME) technology leads to enhanced solubility.
PAP-Q2-18-CL-007 -
Inside Mergers & Acquisitions
Innovation and efficiency are both key to successful drug development and commercialization.
PAP-Q2-18-CL-001 -
Changes in the Biopharma Industry: from Minor to Major Evolution
The biopharmaceutical industry continues to grow rapidly. Targeted biologics are helping treat previously untreatable diseases.
PAP-Q2-18-NI-002 -
Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile
The clinical trial paradigm has shifted.
PAP-Q2-18-CL-002 -
Taking Middle-Market CROs and CDMOs to the Next Level
Smaller outsourcing organizations often need assistance moving to the next level.
PAP-Q2-18-CL-003 -
Addressing Development Challenges for Complex Biologic Drug Candidates
Biotherapeutics identified as potential drug candidates are increasingly complex.
PAP-Q2-18-CL-004 -
Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence
Next-generation viral vector and gene therapy manufacturing facilities must be flexible.
PAP-Q2-18-CL-005 -
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
As biologic drugs become more complex and sophisticated, biopharmaceutical companies increasingly need the support of contract development and manufacturing organizations (CDMOs) with advanced capabilities and technology platforms that are consistently implemented across scales and geographies.
PAP-Q2-18-CL-006 -
Building a Biologics Business from the Ground Up
Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy.
PAP-Q2-18-CL-008 -
Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility
Manufacturing in multi-product facilities affords numerous advantages- and challenges.
PAP-Q2-18-CL-009 -
State-of-the-Art Biologics Manufacturing in an Unexpected Location
Biotechpharma UAB, located in Vilnius, is exporting biologic drug substances worldwide.
PAP-Q2-18-CL-010 -
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
Viral vector manufacturers involved in all stages of clinical-trial-material and commercial product production rely on single-use (SU) technologies.
PAP-Q2-18-CL-011 -
Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance
Oral solid dosage (OSD) remains the preferred dosage delivery form for the formulation of many of today’s drug products.
PAP-Q2-18-CL-012 -
Strengthening the Outsource Service Offering through Integration
Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing.
PAP-Q2-18-CL-013 -
Corporate Social Responsibility as a Driver for Improved Sustainability
The pharmaceutical industry must respond to growing expectations regarding the environmental impact of medicinal products and manufacturing.
PAP-Q2-18-CL-014 -
Challenges for Next-Generation Biological Therapeutics Discovery and Development
In the last three and half decades, the focus of drug discovery and development has gradually shifted to large, complex molecular entities — therapeutic biologics.
PAP-Q2-18-FA-001 -
Thinking a Generation Ahead: Biologics-Based Therapy
Whether dealing with stem cells, CRISPR Cas-9 technology or antibody-drug conjugates, there is no shortage of innovation - the challenge is scaling up.
PAP-Q2-18-FA-002 -
Finishing Touches – The Future of Fill-Finish and Pharma Packaging
Fill-finish has remained relatively stable in spite of myriad developments in the industry over the last decade.
PAP-Q2-18-FA-003 -
Maximizing ROI through Equipment Liquidation
Cost pressures are significant drivers for pharmaceutical manufacturers seeking to eliminate redundancies and increase productivity and efficiency.
PAP-Q2-18-CL-015 -
Experience Meets Flexibility
Advances in rapid synthesis technologies are leading to the preparation of new classes of compounds with attractive therapeutic properties.
PAP-Q2-18-CL-016 -
Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing
Most often developed as injectable formulations, a few “oral peptide” drugs have been approved in recent years.
PAP-Q2-18-CL-017 -
Achieving Controlled Nucleation During Aseptic Lyophilization
Controlled nucleation is essential for obtaining high-quality lyophilized products with intra- and inter-batch consistency.
PAP-Q2-18-CL-018 -
BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities
Since their introduction, biologic drugs have shown great potential to treat diseases not possible to remedy with traditional small-molecule drugs.
PAP-Q2-18-CL-019 -
Providing Flexible Capabilities to Meet Market Demand for Sterile Fill-Finish Services
The fill-finish step in the manufacturing of drugs is the last step completed before a product is packaged and delivered to the patient.
PAP-Q2-18-CL-020 -
DOPING – Famous Cases, Substances and Values in Sports
Doping remains a constant threat to the ethics and values in professional sports, as well as on the amateur level.
PAP-Q2-18-NI-003
-
Reducing Time to Market with Targeted Regulatory Affairs Support
Regulatory affairs activities are essential components of any drug development and commercialization program, explains Maryse Phan, Head of Regulatory Affairs for API Manufacturing, Servier CDMO.
-
Overcoming Formulation Challenges with Liquid-fill Capsules
Eli Elias, Director of Business Development for CapsCanada discusses how liquid-filled hard-shell capsules enable formulators to overcome challenges with complex API.
-
Oral Solid Dose Manufacturing Efficiency is Driving New Attention to Plant Design
Witold Lehmann, PE, Senior Process Engineer for CRB USA explains the drivers behind strategic planning and efficient production.
-
Building a Biologics Business from the Ground Up
Achieving success requires the right strategy, explains Hannes Teissl, Vice President, Biologics at Polpharma Biologics.
-
DOPING – Famous Cases, Substances and Values in Sports
Doping remains a constant threat to the ethics and values in professional sports, as well as on the amateur level.
-
Five Tips to Ensure Faster Equipment Procurement and Installation
Used equipment is readily available, cuts lead time for delivery and install, and allows faster product launch, says Jim Coyne, Business Development/Sales at Federal Equipment Company.
-
Roche and Foundation Medicine Reach Definitive Merger Agreement to Accelerate Broad Availability of Comprehensive Genomic Profiling in Oncology
Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalized medicines and care for patients with cancer.
-
Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801
Up to 48 subjects will be enrolled, including 24 healthy volunteers and 24 subjects with type 1 diabetes.
-
Progress on New Antiviral Drugs at Chimerix
Company reports positive results for treatments against smallpox and norovirus.
-
Successful IPO for Verrica Pharmaceuticals
Company raised $75 million, which will be used to fund a phase 3 study for its treatment of skin infections.
-
Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
Paris, France and Ghent, Belgium - Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.
The Squeeze-out period commenced on May 22, 2018, in accordance with applicable Belgian and U.S. law, following the acquisition by Sanofi of over 95% of the outstanding shares of Ablynx upon settlement of the initial acceptance period of its tender offer for Ablynx.
On June 12, 2018, upon expiration of the Squeeze-out period, 2,893,201 shares (including 7,163 shares represented by ADSs) and 8 convertible bonds of Ablynx were tendered in the Squeeze-out.
The Securities tendered during the Squeeze-out period are expected to be settled on or about June 19, 2018.
All shares (including all shares represented by ADSs) and all convertible bonds of Ablynx not tendered during the Squeeze-out are deemed transferred to Sanofi by operation of law. The funds required for the payment of the price thereof are kept with the Bank for Official Deposits (Deposito- en Consignatiekas / Caisse des dépôts et consignations). The former Ablynx holders of these Securities retain the right to receive EUR 45.00 per share (or ADS) and EUR 393,700.78 per convertible bond. In order to receive these amounts, they must contact the Bank for Official Deposits, where the funds will remain available.
On June 13, 2018, (i) the shares of Ablynx were delisted from the regulated market of Euronext Brussels, (ii) the ADSs were delisted from NASDAQ Global Select Market and (iii) the convertible bonds were delisted from the open market Frankfurt MTF (Freiverkehr).Sanofi contacts
Media Relations Contact
Laurence Bollack
Tel.: +33 (0)1 53 77 46 46
mr@Sanofi.com
Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@Sanofi.com
Ablynx contacts
Dr Edwin Moses
CEO
Tel.:+32 (0)9 262 00 07
Mob.: +32 (0)473 39 50 68
edwin.moses@ablynx.com
Lies Vanneste
Director IR
Tel.: +32 (0)9 262 0137
Mob: +32 (0)498 05 35 79
lies.vanneste@ablynx.com -
Building Healthcare Brands through Recognizable Capsules
Differentiation and establishment of brand recognition are as important for drug products as they are for consumer goods, says Jim Taggart, Plant Manager, CapsCanada.
-
Optimizing API Production as a True Manufacturing Partner
Jim Scandura, Executive Vice President, Chief Operating Officer at Avara Pharmaceutical Service discusses serving as a partner for API production.
-
Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing
Ariana Nagel, Director of Product Development, R&D and and Matthew Ferrell, Director of Analytical Development at UPM Pharmaceuticals explain the benefits and challenges of peptide therapies.
-
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
Richard Snyder, Ph.D., Chief Scientific Officer and Founder; Christopher Murphy, Chief Manufacturing Officer; Susan D'costa, VP Development and Cameron Jones, Quality Assurance Director at Brammer Bio explain how to strengthen security of supply in viral vector manufacturing.
-
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies.
President & CEOAGC Biologics -
Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility
Peter Boeddeker, Director of Quality Management at Baxter BioPharma Solutions describes the challenges and advantages of multi-product facilities.
-
Cellectic CAR-T Therapy Contains Safety Switch and More
CubiCAR cells are designed to be killed by the monoclonal antibody, rituximab, in patients with an overactive immune response.
-
New Diagnostic Tool for Heart Disease Based on CRISPR Technology
Researchers at Stanford University developed the tool, which combines gene editing and disease modeling.
-
A Key to the Cage: Opening the Living Membrane Gate
For the first time ever, scientists have accurately described the process of pore formation in lipid membranes and carried out computer simulations of their formation and evolution.
THE ROAD TO BIO: THE EXTENDED STORY
View AllRoad To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestNew Diagnostic Tool for Heart Disease Based on CRISPR Technology
Jun 21, 2018 10:11:07 AM PAO-M06-18-NI-016Reducing Time to Market with Targeted Regulatory Affairs Support
Jun 20, 2018 10:31:31 AM PAO-06-18-CL-003Could a Bispecific Antibody Be A Functional Cure for AIDS?
Jun 19, 2018 1:14:03 PM PAO-M06-18-NI-015China Grants First Approval for PD-1/L1 Checkpoint Inhibitor
Jun 19, 2018 1:11:20 PM PAO-M06-18-NI-014French Pharma Company Ipsen Moves US Headquarters from New Jersey to Boston
Jun 15, 2018 1:00:09 PM PAO-M06-18-NI-013Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?
Jun 15, 2018 12:53:46 PM PAO-M06-18-NI-012HPAPI’s and Two-Piece Liquid-Fill Capsules: The Perfect Match
Jun 14, 2018 3:42:01 PM PAO-06-18-CL-001Hormone Therapy Appears to Be the Best Bet for Treating Early Breast Cancer
Jun 14, 2018 1:00:03 PM PAO-M06-18-NI-011Pfizer Expands Investment in Biotech through Pfizer Ventures
Jun 14, 2018 12:55:15 PM PAO-M06-18-NI-010FDA Approves Venclexta/Rituxan Combination Treatment for Leukemia
Jun 12, 2018 2:35:44 PM PAO-M06-18-NI-009Preliminary Data Suggests DENKI Pain Blockers Don’t Have Abuse Potential
Jun 12, 2018 2:29:55 PM PAO-M06-18-NI-008
TOPICS
View All TopicsPRESS RELEASES
View All-
West Appoints Bernard Birkett to Chief Financial Officer
Jun 22, 2018 7:00:00 AM -
Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
Jun 22, 2018 7:00:00 AM -
Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801
Jun 22, 2018 7:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
